| Business Summary | | Connetics
Corporation's
commercial
business
is
focused
on
the
dermatology
marketplace.
The
Company
markets
three
pharmaceutical
products.
Its
two
dermatology
products
include
Luxiq
for
mild
to
moderate
scalp
dermatoses,
and
Olux
for
moderate
to
severe
scalp
dermatoses.
The
Company
also
sells
Ridaura,
a
product
to
treat
rheumatoid
arthritis.
Luxiq
is
a
foam
formulation
of
betamethasone
valerate,
a
mid-potency
topical
steroid
that
is
prescribed
for
the
treatment
of
mild
to
moderate
steroid-responsive
scalp
dermatoses.
Olux
is
a
foam
formulation
of
clobetasol
propionate,
a
prescribed
super-high-potency
topical
steroid.
Ridaura
is
an
oral
formulation
of
a
gold
salt
for
the
treatment
of
rheumatoid
arthritis,
a
chronic
autoimmune
disease
that
results
in
inflammation
and
erosion
of
the
joints
and
loss
of
mobility.
On
April
20,
2001,
the
Company
acquired
Soltec
Research
Pty
Ltd.,
the
drug
delivery
unit
of
F
H
Faulding
&
Co
Limited,
an
international
pharmaceutical
and
healthcare
company. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Connetics
Corp.
is
engaged
in
the
development
and
commercialization
of
therapeutics
to
address
serious
diseases
involving
the
connective
tissues
of
the
body.
For
the
six
months
ended
6/01,
revenues
fell
34%
to
$16
million.
Net
loss
before
acct'g
change
totaled
$11
million
vs.
an
income
of
$1.4
million.
Results
reflect
the
absence
of
a
milestone
payment
under
a
former
collaboration
agreement,
expenses
related
to
sales
force
expansion,
and
a
$6
million
divestiture
charge. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| G. Kirk Raab, 65 Chairman,
Director | -- | -- | Thomas Wiggans, 49 Pres,
CEO, Director | $557K | $82K | John Higgins, 31 CFO,
Exec. VP- Fin. and Admin. | 327K | 256K | C. Gregory Vontz, 40 COO | 325K | -- | Linda Fenney, M.D. Sr.
VP, Clinical Research | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|